Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial-Reference-Cited by-同舟云学术

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial

Published:2017-01-25 Issue:3 Volume:19 Page:387-393
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Neal Bruce¹²³⁴,Perkovic Vlado¹⁵,Matthews David R.⁶,Mahaffey Kenneth W.⁷,Fulcher Greg⁵,Meininger Gary⁸,Erondu Ngozi⁸,Desai Mehul⁸,Shaw Wayne⁸,Vercruysse Frank⁹,Yee Jacqueline⁸,Deng Hsiaowei⁸,de Zeeuw Dick¹⁰,

Affiliation:

1. The George Institute for Global Health; Sydney Australia

2. The Charles Perkins Centre; University of Sydney; Sydney Australia

3. Royal Prince Alfred Hospital; Sydney Australia

4. Imperial College London; London UK

5. The Royal North Shore Hospital; University of Sydney; Sydney Australia

6. University of Oxford; Oxford UK

7. Department of Medicine, Stanford Center for Clinical Research (SCCR); Stanford University; Stanford California

8. Janssen Research & Development, LLC; Raritan New Jersey

9. Janssen Research & Development; Beerse Belgium

10. University Medical Center Groningen; University of Groningen; Groningen The Netherlands

Funder

Janssen Research and Development

Australian National Health and Medical Research Council

Janssen

Baxter International

AbbVie

Astellas

Boehringer Ingelheim

AstraZeneca

Eli Lilly

Merck

GlaxoSmithKline

NIHR

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12829/fullpdf

Reference25 articles.

1. United States Renal Data Systems USRDS annual data report: epidemiology of kidney disease in the United States 2015 http://www.usrds.org/2015/view/Default.aspx

2. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes;Parving;N Engl J Med,2001

3. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy;Brenner;N Engl J Med,2001

4. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes;Lewis;N Engl J Med,2001

5. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial;Baigent;Lancet,2011

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2024 ESC Guidelines for the management of chronic coronary syndromes;European Heart Journal;2024-08-30

2. An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes;Diabetes, Obesity and Metabolism;2024-07-22

3. Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial;Diabetes, Obesity and Metabolism;2024-05-28

4. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes;Cochrane Database of Systematic Reviews;2024-05-21

5. Natriuretic Peptides and Prognosis in Patients With Type 2 Diabetes Mellitus and High Risk for Cardiovascular Events;Journal of Cardiac Failure;2024-04